Dr. Paul Sax outlines the differences between two combination HIV regimens, in
HIV and ID Observations.
The FDA recently approved a new fixed-dose combination tablet (elvitegravir, cobicistat, FTC, and tenofovir alafenamide) for treating HIV infection. In the latest HIV and ID Observations blog post, Dr. Paul Sax outlines the differences between ECF-TAF and a similar, existing one-pill-a-day treatment, ECF-TDF (elvitegravir, cobicistat, FTC, and tenofovir disoproxil fumarate).